{
    "clinical_study": {
        "@rank": "18337", 
        "acronym": "AMPACT1", 
        "arm_group": {
            "arm_group_label": "AM-101 injection", 
            "arm_group_type": "Experimental", 
            "description": "AM-101 gel for intratympanic injection"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this research study is to test the safety and local tolerance of repeated\n      treatment cycles of AM-101."
        }, 
        "brief_title": "AM-101 in the Treatment of Post-Acute Tinnitus 1", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Tinnitus", 
        "condition_browse": {
            "mesh_term": "Tinnitus"
        }, 
        "detailed_description": {
            "textblock": "This open-label extension study is assessing the safety and local tolerance of repeated\n      treatment cycles of AM-101 in subjects previously treated in the scope of the TACTT2 study\n      (NCT01803646)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Completion of TACTT2 study;\n\n          -  Negative pregnancy test (woman of childbearing potential);\n\n          -  Willing and able to attend the study visits during at least one treatment cycle.\n\n        Other protocol-defined inclusion criteria may apply.\n\n        Exclusion Criteria:\n\n          -  Adverse event leading to treatment discontinuation in TACTT2;\n\n          -  Meniere's Disease, endolymphatic hydrops, acoustic neuroma, severe or fluctuating\n             hearing loss, otitis media, otitis externa, abnormality of tympanic membrane;\n\n          -  Ongoing drug-based therapy for otitis media or otitis externa;\n\n          -  Drug-based therapy known as potentially tinnitus-inducing;\n\n          -  Other treatment of tinnitus;\n\n          -  Drug abuse or alcoholism;\n\n          -  Subjects with psychiatric diseases requiring drug treatment;\n\n          -  Use of  antidepressant or anti-anxiety medication;\n\n          -  Any clinically relevant disorder or abnormality in physical examination;\n\n          -  Women who are breast-feeding, pregnant or who are planning to become pregnant during\n             the study;\n\n          -  Women of childbearing potential who are unwilling or unable to practice\n             contraception.\n\n        Other protocol-defined exclusion criteria may apply."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "76 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "330", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01934010", 
            "org_study_id": "AM-101-CL-12-03"
        }, 
        "intervention": {
            "arm_group_label": "AM-101 injection", 
            "description": "AM-101 gel for intratympanic injection", 
            "intervention_name": "AM-101", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "June 3, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Cincinnati", 
                    "country": "United States", 
                    "state": "Ohio", 
                    "zip": "45227"
                }, 
                "name": "Medpace"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "AM-101 in the Post-Acute Treatment of Peripheral Tinnitus 1 (AMPACT1) - an Open-Label Extension to the TACTT2 Study", 
        "overall_contact": {
            "email": "auris-trials@medpace.com", 
            "last_name": "Eaton", 
            "phone": "+1.513.579.9911"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "Canada: Health Canada"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Occurrence of deterioration in hearing threshold in the treated ear(s)", 
            "measure": "Hearing threshold", 
            "safety_issue": "Yes", 
            "time_frame": "Up to Day 203"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01934010"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Difference and occurence of deterioration of hearing threshold in the treated ear(s)", 
                "measure": "Hearing threshold", 
                "safety_issue": "Yes", 
                "time_frame": "Up to Day 252"
            }, 
            {
                "description": "Occurrence and severity of adverse events and serious adverse events", 
                "measure": "Adverse events and serious adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Throughout subject study participation"
            }
        ], 
        "source": "Auris Medical, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Auris Medical, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}